May 13, 2020
Bugworks Research, Inc., is a company focused on producing a next
generation
antibiotic in light of
antibiotic resistance.
Dr. Datta details surrounding issues, including
Dr. Santanu Datta is the CSO of
Bugworks, Inc., and has been working in the field of infectious
disease for decades. He begins telling listeners about the
background of
antibiotic development, highlighting the difference it has
made.
He explains why it has been difficult to develop new
antibiotics from both a market and scientific perspective. He
also explains the mechanisms of antibiotic and bacteria
interaction, from the parts the antibiotics have traditionally
targeted to the types of adaptations and evolutions bacteria are
able to make to impede antibiotics, resulting in
antibiotic resistance.
He then talks about his
company's work to make a new broad spectrum antibiotic that targets
the most dangerous bacteria hospitals face in one
antibiotic, from E. coli to Staphylococcus aureus to other common bacteria in hospital patients.
Therefore, doctors may use this in an IV form when they don't have
time to wait for test results because of the health risks to the
patient.
Dr. Datta explains that his new generation
antibiotic targets two parts of the bacteria at once, limiting
its ability to escape unharmed. One of the targets includes the
enzyme bacteria require for replication. He also explains their
approval process as they head towards phase 1 and adds that they
are funded by Carb-x.
For more, see the company's web site at https://bugworksresearch.com/